In order to gather stakeholder input on the initiatives explained in the Biosimilar Action Plan unveiled by FDA Commissioner Scott Gottlieb, MD, last week, the FDA has announced that it will hold a public hearing on the plan on September 4, 2018.
In order to gather stakeholder input on the initiatives explained in the Biosimilar Action Plan unveiled by FDA Commissioner Scott Gottlieb, MD, last week, the FDA has announced that it will hold a public hearing on the plan on September 4, 2018.
The action plan addressed 4 key areas intended to improve biosimilar competition:
The “FDA is soliciting input from the public on how to facilitate greater availability of biosimilar and interchangeable products while retaining the balance between competition and innovation that Congress intended to achieve under the [Biologics Price Competition and Innovation Act],” according to the agency’s announcement. In particular, the FDA is interested in how it can leverage its existing statutory authority to regulate biologics and biosimilars to address issues around the current lack of competition in the market.
Within the announcement, the FDA listed specific questions on which it would like to receive stakeholder feedback, including how the agency can help biosimilars reach patients more quickly after approval, what additional information should be included in the Purple Book to make it more useful, what new steps the agency can take to facilitate evolution of the biologics and biosimilars marketplace, what the agency can do to help reduce development costs without sacrificing safety and quality of biosimilars, how the agency can facilitate multinational development programs that may include reference products licensed outside the United States, and how the FDA can ensure that changes to biologics do not inappropriately deter biosimilar competition.
Electronic comments may be submitted to the Federal Register until September 21, 2018.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.